• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00
    Get the next $ARTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the

      2/20/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial

      11/12/24 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

      SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      9/3/24 4:18:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

      SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      8/1/24 7:00:07 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baker Daniel G.

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      1/29/25 4:33:38 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Baker Daniel G.

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      1/29/25 4:32:16 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Moore Alison

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      10/22/24 8:18:32 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ARTV
    SEC Filings

    See more

    $ARTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Artiva Biotherapeutics Inc.

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      1/29/25 4:07:29 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

      10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      11/12/24 4:10:12 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      11/12/24 4:07:59 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

      SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

      10/22/24 4:05:00 PM ET
      $ALLO
      $ARTV
      $CDXS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Chemicals
      Industrials